OSTX

OS Therapies Incorporated

1.89 USD

Last updated Sep 4, 20:07 UTC

Yesterday HIGH

$1.84

Yesterday LOW

$1.74

52w HIGH

$2.36

52w LOW

$1.15

EPS

-0.20

PE

-9.45

Next Earnings

Nov 16, 2026

Overview News Government Trades Fundamentals

OS Therapies Incorporated stock is up 18.12% since 30 days ago. The next earnings date is Nov 16, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 September’s closed higher than August.

Vandana Singh

Tue Jun 2, 2026

OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings

OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.
Benzinga Newsdesk

Tue Jun 2, 2026

OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year Mark

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated clinical efficacy data
Benzinga Newsdesk

Fri May 29, 2026

OS Therapies Confirms It Will Release 2.5-Yr Overall Survival Data From Phase 2b Clinical Trial OST-HER2 In Prevention Or Delay Of Recurrence In Fully-Resected Pulmonary Metastatic Osteosarcoma During 2026 ASCO Annual Meeting
Benzinga Newsdesk

Fri May 29, 2026

OS Therapies Announces Publication Of Four Articles Related To OST-HER2 And/Or Osteosarcoma In Drug Discovery World
Benzinga Newsdesk

Tue May 19, 2026

Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13

Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the price target from $14 to $13.
Benzinga Insights

Mon May 18, 2026

Earnings Scheduled For May 18, 2026
Benzinga Newsdesk

Mon May 18, 2026

OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate

OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per share from the same
Benzinga Newsdesk

Thu Apr 30, 2026

OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2
Benzinga Newsdesk

Mon Apr 27, 2026

OS Therapies To Host Conference Call On April 30 To Review Data That Supported Recent PCT International Application For OST-HER2 Pharmacodynamic Biomarker1 As Surrogate Clinical Efficacy Endpoint
Benzinga Newsdesk

Thu Apr 16, 2026

OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform

New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responsesCompany to host conference call later in April 2026

LLY $1,143.03 USD

LRCX $305.62 USD

LULU $100.45 USD

SNDK $1,723.40 USD

TWST $124.44 USD

SMCI $39.32 USD

ALAB $312.28 USD

NVTS $11.76 USD